Inhibrx, Inc. Common Stock

INBX

Capitalización de mercado USD 1787 M

SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").

SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issued" basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the "Merger") at the Company's special meeting of stockholders, which will be held on May 24, 2024. As a result, shares of SpinCo common stock are expected to begin trading on a "when-issued" basis on Nasdaq on May 28, 2024 (rather than May 16, 2024), under the symbol "INXB" and under "Inhibrx Biosciences, Inc." When-issued trading of shares of SpinCo common stock will continue until the distribution of shares of SpinCo common stock in the Spin-Off occurs.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will.

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p.m.

Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago.

SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights Sale of INBRX-101 to Sanofi: In January 2024, the Company announced that it entered into a definitive agreement with Aventis, Inc. ("Aventis"), a subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all of the assets and liabilities associated with INBRX-101 ("the Merger").

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will.

Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.

MILWAUKEE , Jan. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join https://www.ademilaw.com/case/inhibrx-inc or call Guri Ademi toll-free at 866-264-3995.